HOME > ORGANIZATION
ORGANIZATION
- July-September Generic Share at 43.1% under New Formula: JGA
February 6, 2014
- JPWA to File Notification to Form Cartel for Uniform Tax Display Method
January 31, 2014
- JPMA Drafting New Rules that Would Restrict Grants and Endowments by Drug Makers to Research Not Involving Their Own Products
January 28, 2014
- Medwatcher Raps Ministry Subcommittees’ Conclusion on HPV Vaccine Side Effects
January 27, 2014
- Generic Industry Can’t Afford “Backsliding” Following FY2014 NHI Pricing Reform: JGA President Yoshida
January 27, 2014
- Dr Teshirogi of JPMA Expresses Concern About Impact of New Price Reduction Rule on Stable Supplies of Long-Listed Drugs, Generics
January 17, 2014
- Generic Makers Likely to Disclose Payments to Medical Institutions from Early May
January 15, 2014
- JPWA Chair Weighs Cartel Deal to Unify Tax Display Methods after Sales Levy Hike
January 14, 2014
- Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
- Japan CRO Association Announces Report on Quality Assurance of Subcontracted Services
January 9, 2014
- New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
- New Price Cut Rule for Long-Listed Products Will Wreak Havoc on Pharmas: FPMAJ Chair
December 27, 2013
- Osaka Bio Fund to Invest 150 Million Yen in Genomix
December 26, 2013
- Mr Koshimizu of MREAC Expresses Concern about Increasing Number of MSLs at a Seminar on Recertification of Managers in Charge of MR Education
December 24, 2013
- Sanofi’s Moulding Picked as New Chair of EFPIA Japan
December 17, 2013
- FPMAJ Chief Renews His Calls to Institutionalize Premium
December 16, 2013
- JPMA Revises Rules for Preparing Product Information Brochures for the 1st Time in 5 years; Bans “Emphasis on Differences” from and “Slander” of Competitors’ Products
December 13, 2013
- Head of JAMS COI Committee Proposes Legislating Ethical Guidelines for Clinical Research
December 11, 2013
- CSIMC Continues to Fire Barbs at “Precursor Premium” Despite Industry Appeal
December 10, 2013
- Mr Umeda of PhRMA Opposes Proposal to Revise Foreign Average Price Adjustment Rule
December 10, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…